{
      "Rank": 430,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "MSCs group refers to treatment with mesenchymal stem cells (1\u00d710^6 cells/kg, intravenously) weekly for 8 doses. Besides, glucocorticoids and cyclosporine (CsA) will be used for treatment concurrently.",
            "Glucocorticoids and CsA will be used for treatment."
      ],
      "ArmGroupInterventionName": [
            "Biological: Mesenchymal stem cells",
            "Drug: Glucocorticoids",
            "Drug: cyclosporine",
            "Drug: Glucocorticoids",
            "Drug: cyclosporine"
      ],
      "ArmGroupLabel": [
            "MSCs group",
            "Control group"
      ],
      "ArmGroupType": [
            "Experimental",
            "Active Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT04692376"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The purpose of this study is to evaluate the efficacy of mesenchymal stem cells in patients with chronic graft-versus-host disease."
      ],
      "BriefTitle": [
            "MSC for Treatment of cGVHD After Allo-HSCT"
      ],
      "CentralContactEMail": [
            "lansinglinren@hotmail.com"
      ],
      "CentralContactName": [
            "Ren Lin, MD"
      ],
      "CentralContactPhone": [
            "+86-020-62787883"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact"
      ],
      "CollaboratorClass": [
            "OTHER",
            "UNKNOWN",
            "OTHER"
      ],
      "CollaboratorName": [
            "Sun Yat-sen University",
            "Xinqiao Hospital, Army Medical University",
            "Peking University People's Hospital"
      ],
      "CompletionDate": [
            "June 30, 2023"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Chronic Graft-versus-host Disease"
      ],
      "ConditionAncestorId": [
            "D000007154"
      ],
      "ConditionAncestorTerm": [
            "Immune System Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC20",
            "All",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Immune System Diseases",
            "All Conditions",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Graft Versus Host Disease",
            "Graft Versus Host Disease",
            "Chronic Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafId": [
            "M8341",
            "M9352",
            "T2832",
            "T1303"
      ],
      "ConditionBrowseLeafName": [
            "Graft vs Host Disease",
            "Immune System Diseases",
            "Homologous Wasting Disease",
            "Chronic Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "low",
            "high",
            "high"
      ],
      "ConditionMeshId": [
            "D000006086"
      ],
      "ConditionMeshTerm": [
            "Graft vs Host Disease"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "Allogeneic hematopoietic stem cell transplantation(allo-HSCT) can cure many hematologic diseases. Although great progress has been made in the prevention and treatment of side effects associated with transplantation,chronic graft-versus-host disease(cGVHD) remains an important complication that occurs in about 50% patients. The mortality of cGVHD and its complication could reach up to 50%,and cGVHD seriously influence the quality of life. At present, the first line treatment of cGVHD remains in discussion.\n\nMesenchymal stem cells (MSCs) are a form of multipotent adult stem cells that can be isolated from bone marrow (BM), adipose tissue, and cord blood. Clinical applications of human MSCs are evolving rapidly with goals of improving hematopoietic engraftment, preventing and treating GVHD after allo-HSCT and so on. However, the efficacy of treatment of cGVHD remains undetermined.\n\nIn the present study, the investigators will prospectively evaluate the efficacy and safety of ex-vivo-expanded MSCs in treating patients with cGVHD."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nA patient age of 18-65 years\nRecipients of allogeneic hematopoietic stem cell transplantation Patients with moderate/ severe cGVHD without systemic treatment\nSubjects (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study\n\nExclusion Criteria:\n\nAny abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)\nPrimary disease relapse\nExpected lifetime less than 3 months\nPatients with any conditions not suitable for the trial (investigators' decision)"
      ],
      "EnrollmentCount": [
            "152"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000004791",
            "D000045504",
            "D000007166",
            "D000007155",
            "D000045505",
            "D000000935",
            "D000000890",
            "D000003879",
            "D000018501",
            "D000065095",
            "D000006728",
            "D000006730"
      ],
      "InterventionAncestorTerm": [
            "Enzyme Inhibitors",
            "Molecular Mechanisms of Pharmacological Action",
            "Immunosuppressive Agents",
            "Immunologic Factors",
            "Physiological Effects of Drugs",
            "Antifungal Agents",
            "Anti-Infective Agents",
            "Dermatologic Agents",
            "Antirheumatic Agents",
            "Calcineurin Inhibitors",
            "Hormones",
            "Hormones, Hormone Substitutes, and Hormone Antagonists"
      ],
      "InterventionArmGroupLabel": [
            "MSCs group",
            "Control group",
            "MSCs group",
            "Control group",
            "MSCs group"
      ],
      "InterventionBrowseBranchAbbrev": [
            "Infe",
            "ARhu",
            "Derm",
            "All",
            "Infl",
            "ANeo",
            "AnEm",
            "NeuroAg",
            "Gast"
      ],
      "InterventionBrowseBranchName": [
            "Anti-Infective Agents",
            "Antirheumatic Agents",
            "Dermatologic Agents",
            "All Drugs and Chemicals",
            "Anti-Inflammatory Agents",
            "Antineoplastic Agents",
            "Antiemetics",
            "Neuroprotective Agents",
            "Gastrointestinal Agents"
      ],
      "InterventionBrowseLeafAsFound": [
            "Impact",
            "Impact",
            "Postprandial"
      ],
      "InterventionBrowseLeafId": [
            "M18113",
            "M5882",
            "M8199",
            "M13272",
            "M1833",
            "M10901",
            "M10902",
            "M229437",
            "M211896",
            "M248768",
            "M9364",
            "M9353",
            "M3406",
            "M5404",
            "M10948",
            "M3366",
            "M6226",
            "M19757",
            "M29605",
            "M8941",
            "M8940"
      ],
      "InterventionBrowseLeafName": [
            "Cyclosporine",
            "Cyclosporins",
            "Glucocorticoids",
            "Prednisolone",
            "Methylprednisolone Acetate",
            "Methylprednisolone",
            "Methylprednisolone Hemisuccinate",
            "Prednisolone acetate",
            "Prednisolone hemisuccinate",
            "Prednisolone phosphate",
            "Immunosuppressive Agents",
            "Immunologic Factors",
            "Antifungal Agents",
            "Clotrimazole",
            "Miconazole",
            "Anti-Infective Agents",
            "Dermatologic Agents",
            "Antirheumatic Agents",
            "Calcineurin Inhibitors",
            "Hormones",
            "Hormone Antagonists"
      ],
      "InterventionBrowseLeafRelevance": [
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "Mesenchymal stem cells (MSCs) will be intravenously infused via a central venous catheter(at a dose of 1\u00d710^6 cells/kg, over 15 mins) weekly. MSCs will be administrated for 8 doses.",
            "Glucocorticoids (i.e. Methylprednisolone) will be used with an initial dose of 1mg/kg.",
            "Cyclosporine (CsA) will be used with an initial dose of 2.5mg/kg/d and adjusted according to the concentration of CsA. The targeted concentration is 200-300 ng/Ml."
      ],
      "InterventionMeshId": [
            "D000016572",
            "D000003524",
            "D000005938"
      ],
      "InterventionMeshTerm": [
            "Cyclosporine",
            "Cyclosporins",
            "Glucocorticoids"
      ],
      "InterventionName": [
            "Mesenchymal stem cells",
            "Glucocorticoids",
            "cyclosporine"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological",
            "Drug",
            "Drug"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Hematopoietic Stem Cell Transplantation",
            "Chronic Graft-versus-host disease",
            "Mesenchymal Stem Cells"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "December 31, 2020"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "December 29, 2020"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Nanfang Hospital of Southern Medical University"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Guangzhou"
      ],
      "LocationContactEMail": [
            "lansinglinren@hotmail.com"
      ],
      "LocationContactName": [
            "Ren Lin, MD",
            "Qifa Liu"
      ],
      "LocationContactPhone": [
            "+86-020-61641613"
      ],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [
            "Contact",
            "Principal Investigator"
      ],
      "LocationCountry": [
            "China"
      ],
      "LocationFacility": [
            "Department of Hematology,Nanfang Hospital, Southern Medical University"
      ],
      "LocationState": [
            "Guangdong"
      ],
      "LocationStatus": [
            "Recruiting"
      ],
      "LocationZip": [
            "510515"
      ],
      "MaximumAge": [
            "65 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Mesenchymal Stem Cell for Treatment of Chronic Graft-versus-host Disease After Allogenetic Hematopoietic Stem Cell Transplantation"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Nanfang Hospital of Southern Medical University"
      ],
      "OrgStudyId": [
            "MSC-cGVHD-2020"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Nanfang Hospital of Southern Medical University"
      ],
      "OverallOfficialName": [
            "Qi-fa Liu, MD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Recruiting"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "December 31, 2022"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "Overall response rate \uff08ORR\uff09includes complete response (CR) and part response (PR)."
      ],
      "PrimaryOutcomeMeasure": [
            "ORR"
      ],
      "PrimaryOutcomeTimeFrame": [
            "12 weeks after the first dose of MSCs"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [
            "Nanfang Hospital of Southern Medical University"
      ],
      "ResponsiblePartyInvestigatorFullName": [
            "Qifa Liu"
      ],
      "ResponsiblePartyInvestigatorTitle": [
            "Professor"
      ],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Principal Investigator"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "Overall survival (OS)",
            "Disease-free survival (DFS)",
            "EBV DNA-emia refers to detection of EBV DNA in peripheral blood via PCR.",
            "CMV DNA-emia refers to detection of CMV DNA in peripheral blood via PCR.",
            "Poor graft function (PGF) refers to a slow or incomplete recovery of blood cell counts (ANC \u22640.5x10^9/L and PLT \u226420x10^9/L) by +28 days after allo-HSCT or a fall in blood cell counts to levels fulfilling the diagnostic criteria for PGF after successful and prompt hematopoietic engraftment."
      ],
      "SecondaryOutcomeMeasure": [
            "OS",
            "DFS",
            "Response rate",
            "EBV DNA-emia",
            "CMV DNA-emia",
            "PGF"
      ],
      "SecondaryOutcomeTimeFrame": [
            "1 year after the first dose of MSCs",
            "1 year after the first dose of MSCs",
            "4 weeks after the first dose of MSCs",
            "1 year after the first dose of MSCs",
            "1 year after the first dose of MSCs",
            "1 year after the first dose of MSCs"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "January 10, 2021"
      ],
      "StartDateType": [
            "Anticipated"
      ],
      "StatusVerifiedDate": [
            "December 2020"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "December 31, 2020"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "December 26, 2020"
      ],
      "StudyFirstSubmitQCDate": [
            "December 29, 2020"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}